Australia to study first interventional neuromodulation platform – BSA bureau

Synchron's Stentrode brain-computer interface system is a fully-implantable therapeutic

US based Synchron Inc., a neurovascular bioelectronic medicine company, has announced that theUniversity of Melbournehas been awarded an AUD$1.5MMedical Research Future Fundgrant from the National Health and Medical Research Council (NHMRC) of the Australian Government to expand the current clinical study ofSynchron's Stentrode.

The study is the first clinical trial to evaluate the safety and efficacy of the Stentrode, the first interventional neuromodulation platform. This technology is designed to translate brain activity from the inside of a blood vessel, and is being explored for its potential to enable hands-free control of devices for people with upper limb paralysis.

"Having this support from the Australian government further validates the importance of our work and our confidence that this technology will lead to the realization of a treatment option with the capability to transform the lives of patients with paralysis," saidThomas Oxley, MD, PhD,CEO of Synchron. "The potential to advance this important work that this grant offers cannot be understated."

The funds will be used to expand the current feasibility study to include:

More:
Australia to study first interventional neuromodulation platform - BSA bureau